Haydar C. Yuksel

Ege, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Seasonal timing of anti-PD-1 therapy and survival outcomes in a real-world pan-cancer cohort.

Seasonal timing of anti-PD-1 therapy and survival outcomes in a real-world pan-cancer cohort.

Journal: Expert review of clinical immunology

Published: June 03, 2026

Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours.

Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours.

Journal: Immunotherapy

Published: April 20, 2026

Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO).

Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO).

Journal: JCO global oncology

Published: March 26, 2026

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501).

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501).

Journal: International journal of cancer

Published: February 09, 2026

Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events.

Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events.

Journal: Expert review of anticancer therapy

Published: January 08, 2026

Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors.

Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors.

Journal: Expert review of anticancer therapy

Published: December 10, 2025

Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group.

Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group.

Journal: Frontiers in oncology

Published: November 28, 2025

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 14, 2025

Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment.

Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment.

Journal: BMC cancer

Published: October 02, 2025

Dynamic lactate dehydrogenase/lymphocyte ratio and C-reactive protein as predictors of mortality after plasma exchange in ANCA-associated vasculitis: A retrospective case control study.

Dynamic lactate dehydrogenase/lymphocyte ratio and C-reactive protein as predictors of mortality after plasma exchange in ANCA-associated vasculitis: A retrospective case control study.

Journal: Medicine

Published: August 14, 2025

Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study.

Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study.

Journal: International journal of cancer

Published: August 13, 2025

Association between immune-related adverse events and recurrence dynamics under adjuvant anti-PD-1 therapy in resected melanoma.

Association between immune-related adverse events and recurrence dynamics under adjuvant anti-PD-1 therapy in resected melanoma.

Journal: Frontiers in oncology

Published: July 22, 2025

Showing 1-12 of 30

Last Updated: 09/26/2026